$599

Abbott’s Libre Duo Approved by FDA; AZ Initiates Pivotal Amylin Studies; New Lilly Medicare Obesity Ad; Lilly Initiates First Clazakizumab Study; Google Pixel Watch Non-Invasive Insulin Resistance; Revier Seed Financing for HFpEF and ASCVD; Haisco Partners with US-Based VC for Spinout

A series of cardiometabolic-related news items has been observed from Abbott, AstraZeneca, Lilly, Google, Revier Therapeutics, and Haisco Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here